The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Abstract
Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress de novo lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 to obese rodents reverses diabetes and obesity through increasing energy expenditure77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“It is clear that FGF21 treatment elicits significant metabolic changes in many tissues, including the liver and adipose tissues (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [116]
Citations
Cites
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Self-citationCellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Self-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., & Friedman, J. M. (2002) · Science · doi:10.1126/science.1071527 · Cited by 826
Cited by
Sorted by citations
Items 901–995 of 995
Brunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Self-citationLin, Y., Claflin, K. E., Aklan, İ., Morgan, D. A., Sullivan, A. I., Rudolph, M. C., Rahmouni, K., & Potthoff, M. J. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117093 · Cited by 3
Liu, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.079 · Cited by 2
Ozaki‐Masuzawa, Y., Kosaka, H., Abiru, R., Toda, Y., Kawabata, K., Nagata, M., Hara, S., Konishi, M., Itoh, N., Hosono, T., et al. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbab030 · Cited by 2
Production of active human FGF21 using tobacco mosaic virus-based transient expression system
Fan, J., Wang, Y., Huang, S., Xing, S., & Wei, Z. (2021) · Growth Factors · doi:10.1080/08977194.2022.2038148 · Cited by 2
Fibroblast Growth Factor 21 as a Regulator of Energy Metabolism in the Liver and Adipose Tissue
Matikainen, N., & Söderlund, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816093-0.00013-6 · Cited by 2
Chao, Y.-M., Wu, H., Yeh, S.-H., Yang, D., Her, L., & Wu, Y.-L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084211 · Cited by 2
Shinozaki, H., Kawai, S., Gamo-Kawasaki, M., Takei, A., Tsujikado, K., Fukuda, K., Yamauchi, M., Hara, K., Tsuchiya, T., Takebayashi, K., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0570 · Cited by 2
Evaluating Fibroblast Growth Factor 21 (FGF21) Levels Post-Gastric Sleeve Surgery in Obese Patients
Al-Regaiey, K., Iqbal, M., Alzaid, M., Alkaoud, O. A., Alhadyani, M. A., Alagel, O. A., Alshehri, S. S., Altamimi, I., & Alsofayan, S. M. (2024) · Cureus · doi:10.7759/cureus.66122 · Cited by 3
Effect of exercise on Fibroblast Growth Factor 21 levels in healthy males and females
Peterson, M. N., Richardson, K. A., & Funderburk, L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321738 · Cited by 2
The role of fibroblast growth factors in cell and cancer metabolism
Price, J., & Francavilla, C. (2025) · FEBS Letters · doi:10.1002/1873-3468.70199 · Cited by 3
Kiyama, G., Nakashima, K., Shimada, K., Murono, N., Kakihana, W., Imai, H., Inoue, M., & Hirai, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112078 · Cited by 2
Liang, S.-X., & Yan, Y. (2013) · Journal of Medical Hypotheses and Ideas · doi:10.1016/j.jmhi.2013.07.002 · Cited by 2
Fibroblast growth factor-21: A link for glucose homeostasis
Naderali, E. K., Wong, C., & Hussain, M. (2009) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2009.07.002 · Cited by 2
Fibroblast growth factor 21: new insights from human studies
Hansen, J. S., & Plomgaard, P. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000084 · Cited by 2
Exercise and Activation of Brown Adipose Tissue
Lee, H. J. (2018) · The Asian Journal of Kinesiology · doi:10.15758/ajk.2018.20.1.1 · Cited by 2
Matsui, M., Kosaki, K., Akazawa, N., Tanahashi, K., Kuro‐o, M., & Maeda, S. (2019) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.8.195 · Cited by 2
Fibroblast Growth Factor 21 as a Novel Metabolic Regulator
Micanovic, R., Dunbar, J. D., & Kharitonenkov, A. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch14 · Cited by 2
Self-citationA Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis
Elsayed, A. (2020) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Patel, S., Haider, A., Álvarez-Guaita, A., Bidault, G., Moustafa, J. S. E.-S., Guiu‐Jurado, E., Tadross, J. A., Warner, J., Harrison, J., Virtue, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.08.495255 · Cited by 2
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00003-2 · Cited by 2
Bartmańska, M., Więcek, A., & Adamczak, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144266 · Cited by 1
Dietary Insulinogenic Amino Acid Restriction Improves Glucose Metabolism in a Neonatal Piglet Model
Gorton, M. W., Goodarzi, P., Lei, X., Anderson, M. C., Habibi, M., Wilson, N. F., & Pezeshki, A. (2025) · Nutrients · doi:10.3390/nu17101675 · Cited by 1
RNF128 regulates the adaptive metabolic response to fasting by modulating PPARα function
Lin, Y., Liu, P., Tsai, Y., Lin, C., Chen, Y., Sun, J., Chang, Y., Tsai, W., Ding, Y., Liu, C.-W., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01579-4 · Cited by 1
Self-citationSerum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease
Tanaka, T., Suda, G., Ohara, M., Maehara, O., Yoda, T., Fu, Q., Yang, Z., Yasuura, N., Meno, A., Sasaki, T., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1730695 · Cited by 1
Grandl, G., König, A., Metzger, F., Liśkiewicz, A., Hefele, T., Nason, S., Novikoff, A., Al-Refaie, N., Rahman, M. A., Khalil, A., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.05.011 · Cited by 2
Holleboom, A. G., & Schattenberg, J. M. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101957 · Cited by 1
Wali, J. A., Ramos-Nieves, J. M., Binia, A., & van der Beek, E. M. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100713 · Cited by 1
Implantable Drug Delivery Systems Based on the Principles of Osmosis
Culwell, J. A., Gadea, J. R., Peer, C. E., & Wright, J. C. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0554-2_17 · Cited by 1
Yi, X. (2013) · Lincoln (University of Nebraska) · Cited by 1
The Protection of FGF21 on Chronic-Binge Alcohol-Induced Liver Injury
许, 韵. (2016) · Open Journal of Natural Science · doi:10.12677/ojns.2016.44055 · Cited by 1
Seto‐Young, D., Avtanski, D. B., So-Young, K., Sy, V., Liao, E. P., Liu, C., Wan, S., LESSER, M. L., & Poretsky, L. (2017) · Clinical Obstetrics Gynecology and Reproductive Medicine · doi:10.15761/cogrm.1000194 · Cited by 1
Malaikah, S., Willis, S. A., Henson, J. J., Sargeant, J. A., Yates, T. E., Thackray, A. E., Goltz, F. R., Roberts, M. J., Bernard-Deshong, D., Aithal, G. P., et al. (2023) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2022-0445 · Cited by 1
Zhang, X., Zhang, H., Qiang, W., Guo, Y., Wu, D., & Sun, X. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.10.8 · Cited by 1
Omofuma, O. O., Rusiecki, J. A., Petrick, J. L., Falk, R. T., Wheeler, W., Pfeiffer, R. M., Camargo, M. C., & Cook, M. B. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1544 · Cited by 1
Harms, M. (2015) · Scholarly Commons (University of Pennsylvania) · Cited by 1
Fibroblast Growth Factor 19: An Overview of its Diverse Physiological Functions
Ghosh, A. (2015) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000285 · Cited by 1
Protein Structure and Modification of FGFs
Li, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816142-5.00007-2 · Cited by 1
Pathophysiology and Pharmacology of FGFs
Li, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816142-5.00004-7 · Cited by 1
Evaluation of a cell model expressing βKlotho for screening FGF21 analogues
Guo, X., Wang, X., Yuan, Q., Wu, C., Gao, H., Xu, P., Liu, M., Wang, N., Li, D., & Ren, G. (2019) · Cytotechnology · doi:10.1007/s10616-019-00344-z · Cited by 2
Chen, Y., Wu, Q., Gao, Y., Zhang, H., Dong, Z., Li, R., & Xu, C. (2019) · Medycyna Weterynaryjna · doi:10.21521/mw.6343 · Cited by 1
Self-citationEntwicklung und Regulation des braunen Fettgewebes
Tews, D., & Wabitsch, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-59216-8_13 · Cited by 1
Wäse, K., Bartels, T., Schwahn, U., & Kabiri, M. (2023) · Toxicologic Pathology · doi:10.1177/01926233231164097 · Cited by 1
Kwon, R.-W., Lee, S., Kim, T.-W., & Lee, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.18.469147 · Cited by 1
Larson, K. R., Jayakrishnan, D., Sauza, K. A. S., Goodson, M. L., CHAFFIN, A. T. B., Davidyan, A., Pathak, S. J., Fang, Y., Magaña, D. G., Miller, B. F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.27.546599 · Cited by 1
Feasibility of improving manufacturability based on protein engineeringPreprint
Capito, F., Wong, T. H., Faust, C., Brand, K., Dittrich, W., Sommerfeld, M. R., & Langer, T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.23.568267 · Cited by 1
Nelson, B. T. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Braunes Fettgewebe: Die neue Waffe gegen Adipositas?
Fenzl, A., & Kiefer, F. W. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Mashili, F. L. (2012) · Figshare
LY2405310 : un analogue du FGF21 avec une efficacité métabolique partielle
Dubois‐Laforgue, D. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70753-9
Journée d’actualité en diabétologie 2009
Solignac, M. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70068-7
Metabolic signaling under nutrient deprivation
Coelho, D. S., & Luisa, A. (2012) · TDX (Tesis Doctorals en Xarxa)
Karásek, D., Krsková, M., Halenka, M., & Orság, J. (2014)
Thompson, A. C. S. (2014) · ProQuest Demo Repository
Immunological and molecular mechanisms in NAFLD
Copaci, I., Micu, L., Chiriac, G., Mindrut, E., Ismail, G., & Leurzeanu, L. (2015) · Journal of Translational Medicine and Research · doi:10.21614/jtmr-20-4-57
Stéatose et résistance à l’insuline : implication des hépatokines
Bertrand, C., Valet, P., & Castan‐Laurell, I. (2015) · Obésité · doi:10.1007/s11690-015-0492-7
Changes in Cardiotrophin-1 and Fibroblast Growth Factor-21 with Weight Loss
Bowers, R. L. (2009)
Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16
Dushay, J. R., Chui, P. C., Gopalakrishnan, G. S., Crawley, M. B., Fisher, F. M., & Badman, M. K. (2010)
Potensi Terapeutik Fibroblast Growth Factor 21 terhadap Resistensi Insulin
Kurniasari, K., & Arozal, W. (2015) · eJournal Kedokteran Indonesia · doi:10.23886/ejki.3.5049
Towards Examining FGF21 Secretion from Pancreatic Islets in a Microfluidic Device
Green, B. J. (2012) · TSpace (University of Toronto)
Loyd, C. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Schlegel, G., & Justus Liebig University Giessen (2013) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-16589
INDUCTION OF BROWN ADIPOSE TISSUE: A REVIEW
Romauld, S. I., Akilashree, S., & Devi, P. B. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i5.22646
Papel dos PPARs sobre os benefícios imuno-metabólicos promovidos pelo ácido palmitoleico.
de Souza, C. O. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2018.tde-09032018-101759
The Role Of Crebh In Hepatic Energy Regulation Under Metabolic Stress
Mendez, R. (2015) · Human Biology
Ivanova, K. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-3-1-145-108-112
Li, J. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/yy81-0a75
FGF21 mediates corticosteroid-related bone mass loss through PPAR-$\gamma$
Guan, Y., Huang, J., Huang, S., Kasukurthi, M. V., Huang, Y., Li, D., Tan, S., Wang, S., Xin, N., Lin, J., et al. (2019) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm47256.2019.8983042
Ferreira, M. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.100.2020.tde-19122019-134105
Melaku, L. S., & Debela, N. (2020) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_92_20
DONMA, M., ERSELCAN, S. D., Yılmaz, A., Güzel, S., & Donma, O. (2020) · Namık Kemal Tıp Dergisi · doi:10.37696/nkmj.781963
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Developmental signaling pathways in adult energy homeostasis
Antonellis, P. J. (2021) · Figshare · doi:10.25394/pgs.15062292.v1
Wean, J. (2021) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2021.383
Griffin, P. R., & Kumar, N. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.4113957.3893055
Means, A. R. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13865958.15303059
Ladbury, J. E. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737907472.793574673
Mehmood, R. (2011) · doi:10.3998/panc.2011.35
Long-Acting Injections and Implants
(2016) · CRC Press eBooks · doi:10.1201/9781315382579-7
The developing link of metabolic growth factors in insulin resistance
Gao, R., Hassan, W., Shahzadi, A., din, F. U., & Rasheed, H. M. F. (2017) · Journal of Contemporary Pharmacy · doi:10.56770/jcp201705
Lü, C., Jin, L., Bi, J., Jin, H., You, X., Peng, L., Wang, L., Fan, Z., & Wang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2441482/v1
Safina, N. Y., Шакиров, Ш. К., Gaynutdinova, E. R., & Fattakhova, Z. F. (2023) · International Journal of Veterinary Medicine · doi:10.52419/issn2072-2419.2022.4.314
Double knockout of FFAR4 and FGF21 aggravates metabolic disorders in mice
Wei, L., Ye, X., Cui, S., Li, D., & Zhu, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126553
Alves, E. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-17102023-093636
Signaling pathway and pharmacology
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00005-6
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00009-3
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00007-x
Бажан, Н. М., & En, M. (2023) · Успехи физиологических наук · doi:10.31857/s0301179823040033
Jakovleva, T., Kazantseva, A., Mamontova, K. Y., & Bazhan, N. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024020315
Capito, F., Wong, T. H., Faust, C., Brand, K., Dittrich, W., Sommerfeld, M. R., Tiwari, G., & Langer, T. (2024) · Engineering in Life Sciences · doi:10.1002/elsc.202400019 · Cited by 1
Metadata
- Authors
- Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A.
- Affiliations
- Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-08-07
- Volume
- 149
- Issue
- 12
- Pages
- 6018-6027
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2114650931
- Cited by
- 1,031
- References
- 26
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 58 · 2023: 63 · 2022: 57 · 2021: 72 · 2020: 67 · 2019: 76 · 2018: 72 · 2017: 64 · 2016: 78 · 2015: 85 · 2014: 71 · 2013: 62 · 2012: 61
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- FGF21, obesity, diet-induced obesity, ob/ob mice, energy expenditure, fat oxidation, de novo lipogenesis, hepatic steatosis, insulin resistance, leptin resistance, glycemia, lipid excretion, adipose tissue, metabolic therapy
- MeSH terms
- Animals, Body Weight, Energy Intake, Dietary Fats, Energy Metabolism, Fibroblast Growth Factors, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Motor Activity, Obesity, Leptin, Adiposity, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
